FREDRIC N ESHELMAN Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for FREDRIC N ESHELMAN.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of FREDRIC N ESHELMAN. FREDRIC N ESHELMAN is Director in Valeant Pharmaceuticals International, Inc. ($BVF) and CEO in PHARMACEUTICAL PRODUCT DEVELOPMENT INC ($PPDI) and Chief Executive Officer in PHARMACEUTICAL PRODUCT DEVELOPMENT INC ($PPDI) and Director in MEDICINES CO /DE ($MDCO) and Executive Chairman in MEDICINES CO /DE ($MDCO) and Director in Aravive, Inc. ($ARAV) and Director in G1 Therapeutics, Inc. ($GTHX) and Director in EYENOVIA, INC. ($EYEN).
Latest Insider Trading Transactions of FREDRIC N ESHELMAN
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ARAV, BVF, EYEN, GTHX, MDCO, PPDI
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Sep 15 2020 | ARAV | Aravive, Inc. | ESHELMAN FREDRIC N | Director | Option Exercise | A | 5.63 | 16,029 | 90,243 | 16,029 | |
Sep 15 2020 | EYEN | EYENOVIA, INC. | ESHELMAN FREDRIC N | Director | Option Exercise | A | 3.43 | 9,820 | 33,683 | 9,820 | |
Sep 15 2020 | EYEN | EYENOVIA, INC. | ESHELMAN FREDRIC N | Director | Grant | A | 0.00 | 7,288 | 0 | 1,292,787 | 1.3 M to 1.3 M (+0.57 %) |
Jun 12 2020 | GTHX | G1 Therapeutics, I ... | ESHELMAN FREDRIC N | Director | Option Exercise | A | 17.59 | 20,000 | 351,800 | 20,000 | |
Jun 03 2020 | ARAV | Aravive, Inc. | ESHELMAN FREDRIC N | Director | Option Exercise | A | 12.72 | 3,226 | 41,035 | 3,226 | |
Jun 03 2020 | ARAV | Aravive, Inc. | ESHELMAN FREDRIC N | Director | Option Exercise | A | 12.72 | 7,500 | 95,400 | 7,500 | |
Aug 20 2019 | EYEN | EYENOVIA, INC. | ESHELMAN FREDRIC N | Director | Option Exercise | A | 3.11 | 9,057 | 28,167 | 9,057 | |
Aug 20 2019 | EYEN | EYENOVIA, INC. | ESHELMAN FREDRIC N | Director | Grant | A | 0.00 | 8,038 | 0 | 1,285,499 | 1.3 M to 1.3 M (+0.63 %) |
Jun 14 2019 | GTHX | G1 Therapeutics, I ... | ESHELMAN FREDRIC N | Director | Option Exercise | A | 18.47 | 20,000 | 369,400 | 20,000 | |
Jul 26 2018 | EYEN | EYENOVIA, INC. | ESHELMAN FREDRIC N | Director | Option Exercise | A | 6.20 | 4,465 | 27,683 | 4,655 | |
Jul 26 2018 | EYEN | EYENOVIA, INC. | ESHELMAN FREDRIC N | Director | Grant | A | 0.00 | 4,033 | 0 | 1,277,461 | 1.3 M to 1.3 M (+0.32 %) |
Jun 11 2018 | GTHX | G1 Therapeutics, I ... | ESHELMAN FREDRIC N | Director | Option Exercise | A | 38.39 | 10,000 | 383,900 | 10,000 | |
Jun 04 2018 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Executive Chairman | Option Exercise | A | 33.86 | 14,141 | 478,814 | 14,141 | |
Jun 04 2018 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Executive Chairman | Grant | A | 0.00 | 3,766 | 0 | 1,132,149 | 1.1 M to 1.1 M (+0.33 %) |
Feb 06 2018 | EYEN | EYENOVIA, INC. | ESHELMAN FREDRIC N | Director | Buy | P | 10.00 | 335,000 | 3,350,000 | 1,273,428 | 938.4 K to 1.3 M (+35.70 %) |
Dec 11 2017 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Executive Chairman | Buy | P | 26.65 | 100,000 | 2,665,000 | 1,128,383 | 1 M to 1.1 M (+9.72 %) |
Dec 11 2017 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Executive Chairman | Buy | P | 26.46 | 100,000 | 2,646,000 | 1,028,383 | 928.4 K to 1 M (+10.77 %) |
Nov 15 2017 | GTHX | G1 Therapeutics, I ... | ESHELMAN FREDRIC N | Director | Buy | P | 19.73 | 250,000 | 4,932,500 | 250,000 | 0 to 250 K |
Jul 13 2017 | GTHX | G1 Therapeutics, I ... | ESHELMAN FREDRIC N | Director | Option Exercise | A | 15.55 | 20,000 | 311,000 | 20,000 | |
May 30 2017 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Director | Option Exercise | A | 39.39 | 13,577 | 534,798 | 13,577 | |
May 30 2017 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Director | Grant | A | 0.00 | 3,237 | 0 | 928,383 | 925.1 K to 928.4 K (+0.35 %) |
May 24 2017 | GTHX | G1 Therapeutics, I ... | ESHELMAN FREDRIC N | Director | Option Exercise | C | 0.00 | 2,524,233 | 0 | 0 | |
May 24 2017 | GTHX | G1 Therapeutics, I ... | ESHELMAN FREDRIC N | Director | Option Exercise | C | 0.00 | 6,893,224 | 0 | 0 | |
May 24 2017 | GTHX | G1 Therapeutics, I ... | ESHELMAN FREDRIC N | Director | Buy | P | 15.00 | 300,000 | 4,500,000 | 3,439,151 | 3.1 M to 3.4 M (+9.56 %) |
May 24 2017 | GTHX | G1 Therapeutics, I ... | ESHELMAN FREDRIC N | Director | Buy | C | 0.00 | 3,139,151 | 0 | 3,139,151 | 0 to 3.1 M |
May 05 2017 | BVF | Valeant Pharmaceut ... | ESHELMAN FREDRIC N | Director | Grant | A | 0.00 | 25,406 | 0 | 38,298 | 12.9 K to 38.3 K (+197.07 %) |
May 05 2017 | BVF | Valeant Pharmaceut ... | ESHELMAN FREDRIC N | Director | Payment of Exercise | F | 9.66 | 4,904 | 47,373 | 12,892 | 17.8 K to 12.9 K (-27.56 %) |
Dec 08 2016 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Director | Buy | P | 33.19 | 5,501 | 182,578 | 925,146 | 919.6 K to 925.1 K (+0.60 %) |
Dec 08 2016 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Director | Buy | P | 32.51 | 19,188 | 623,802 | 919,645 | 900.5 K to 919.6 K (+2.13 %) |
Dec 08 2016 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Director | Buy | P | 32.90 | 86,587 | 2,848,712 | 900,457 | 813.9 K to 900.5 K (+10.64 %) |
Dec 08 2016 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Director | Buy | P | 33.61 | 172,764 | 5,806,598 | 813,870 | 641.1 K to 813.9 K (+26.95 %) |
Dec 08 2016 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Director | Buy | P | 34.15 | 337,680 | 11,531,772 | 641,106 | 303.4 K to 641.1 K (+111.29 %) |
Jul 06 2016 | BVF | Valeant Pharmaceut ... | ESHELMAN FREDRIC N | Director | Payment of Exercise | F | 23.78 | 26 | 618 | 17,796 | 17.8 K to 17.8 K (-0.15 %) |
Jun 21 2016 | BVF | Valeant Pharmaceut ... | ESHELMAN FREDRIC N | Director | Grant | A | 0.00 | 16,726 | 0 | 17,822 | 1.1 K to 17.8 K (+1,526.09 %) |
May 31 2016 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Director | Option Exercise | A | 37.22 | 14,700 | 547,134 | 14,700 | |
May 31 2016 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Director | Grant | A | 0.00 | 3,426 | 0 | 303,426 | 300 K to 303.4 K (+1.14 %) |
May 13 2016 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Director | Buy | P | 33.68 | 300,000 | 10,104,000 | 300,000 | 0 to 300 K |
Mar 15 2016 | BVF | Valeant Pharmaceut ... | ESHELMAN FREDRIC N | Director | Grant | A | 0.00 | 1,096 | 0 | 1,096 | 0 to 1.1 K |
Nov 25 2015 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Director | Option Exercise | P | 42.00 | 1,000 | 42,000 | 1,000 | |
Sep 01 2015 | MDCO | MEDICINES CO /DE | ESHELMAN FREDRIC N | Director | Option Exercise | A | 33.64 | 24,080 | 810,051 | 24,080 | |
Aug 08 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Gift | G | 0.00 | 39,000 | 0 | 7,965,626 | 8 M to 8 M (-0.49 %) |
Aug 29 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Gift | G | 0.00 | 40,000 | 0 | 7,925,626 | 8 M to 7.9 M (-0.50 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.60 | 25 | 1,090 | 8,004,626 | 8 M to 8 M (0.00 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.58 | 600 | 26,148 | 8,004,651 | 8 M to 8 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.57 | 1,875 | 81,694 | 8,005,251 | 8 M to 8 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.56 | 1,500 | 65,340 | 8,007,126 | 8 M to 8 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.55 | 7,000 | 304,850 | 8,008,626 | 8 M to 8 M (-0.09 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.54 | 600 | 26,124 | 8,015,626 | 8 M to 8 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.53 | 2,400 | 104,472 | 8,016,226 | 8 M to 8 M (-0.03 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.80 | 1,498 | 64,114 | 8,018,626 | 8 M to 8 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.79 | 2,406 | 102,953 | 8,020,124 | 8 M to 8 M (-0.03 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.78 | 1,000 | 42,780 | 8,022,530 | 8 M to 8 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.77 | 1,900 | 81,263 | 8,023,530 | 8 M to 8 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.76 | 6,475 | 276,871 | 8,025,430 | 8 M to 8 M (-0.08 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.75 | 7,202 | 307,886 | 8,031,905 | 8 M to 8 M (-0.09 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.74 | 3,000 | 128,220 | 8,039,107 | 8 M to 8 M (-0.04 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.73 | 5,525 | 236,083 | 8,042,107 | 8 M to 8 M (-0.07 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.72 | 2,324 | 99,281 | 8,047,632 | 8 M to 8 M (-0.03 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.71 | 9,200 | 392,932 | 8,049,956 | 8.1 M to 8 M (-0.11 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.70 | 8,620 | 368,074 | 8,059,156 | 8.1 M to 8.1 M (-0.11 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.69 | 1,000 | 42,690 | 8,067,776 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.68 | 1,200 | 51,216 | 8,068,776 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.66 | 1,600 | 68,256 | 8,069,976 | 8.1 M to 8.1 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.65 | 5,900 | 251,635 | 8,071,576 | 8.1 M to 8.1 M (-0.07 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.64 | 2,270 | 96,793 | 8,077,476 | 8.1 M to 8.1 M (-0.03 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.63 | 4,100 | 174,783 | 8,079,746 | 8.1 M to 8.1 M (-0.05 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.62 | 5,900 | 251,458 | 8,083,846 | 8.1 M to 8.1 M (-0.07 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.61 | 638 | 27,185 | 8,089,746 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.60 | 2,042 | 86,989 | 8,090,384 | 8.1 M to 8.1 M (-0.03 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.59 | 3,400 | 144,806 | 8,092,426 | 8.1 M to 8.1 M (-0.04 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.57 | 1,400 | 59,598 | 8,095,826 | 8.1 M to 8.1 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.55 | 5,700 | 242,535 | 8,095,286 | 8.1 M to 8.1 M (-0.07 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.53 | 3,600 | 153,108 | 8,102,926 | 8.1 M to 8.1 M (-0.04 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.52 | 8,100 | 344,412 | 8,106,526 | 8.1 M to 8.1 M (-0.10 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.83 | 122 | 5,225 | 8,114,626 | 8.1 M to 8.1 M (0.00 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.84 | 300 | 12,852 | 8,114,748 | 8.1 M to 8.1 M (0.00 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.86 | 778 | 33,345 | 8,115,048 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.91 | 1,100 | 47,201 | 8,115,826 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.87 | 445 | 19,077 | 8,116,926 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.90 | 5,000 | 214,500 | 8,117,371 | 8.1 M to 8.1 M (-0.06 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.92 | 2,055 | 88,201 | 8,122,371 | 8.1 M to 8.1 M (-0.03 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.93 | 1,900 | 81,567 | 8,124,426 | 8.1 M to 8.1 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.02 | 1,012 | 43,536 | 8,126,326 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.00 | 5,098 | 219,214 | 8,127,338 | 8.1 M to 8.1 M (-0.06 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.01 | 1,900 | 81,719 | 8,132,436 | 8.1 M to 8.1 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.06 | 2,762 | 118,932 | 8,134,336 | 8.1 M to 8.1 M (-0.03 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.08 | 800 | 34,464 | 8,137,098 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.09 | 290 | 12,496 | 8,137,898 | 8.1 M to 8.1 M (0.00 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.07 | 1,438 | 61,935 | 8,138,188 | 8.1 M to 8.1 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.05 | 1,000 | 43,050 | 8,139,626 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.02 | 396 | 17,036 | 8,140,626 | 8.1 M to 8.1 M (0.00 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.03 | 100 | 4,303 | 8,141,022 | 8.1 M to 8.1 M (0.00 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.11 | 2,000 | 86,220 | 8,141,122 | 8.1 M to 8.1 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.12 | 3,804 | 164,028 | 8,143,122 | 8.1 M to 8.1 M (-0.05 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.10 | 5,503 | 237,179 | 8,146,926 | 8.2 M to 8.1 M (-0.07 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.11 | 2,197 | 94,713 | 8,152,429 | 8.2 M to 8.2 M (-0.03 %) |
Feb 22 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Option Exercise | A | 44.78 | 100,000 | 4,478,000 | 100,000 | |
Dec 13 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Gift | G | 0.00 | 6,000 | 0 | 8,254,626 | 8.3 M to 8.3 M (-0.07 %) |
Dec 13 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Gift | G | 0.00 | 190,000 | 0 | 8,260,626 | 8.5 M to 8.3 M (-2.25 %) |
Dec 28 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | J | 0.00 | 100,000 | 0 | 8,154,626 | 8.3 M to 8.2 M (-1.21 %) |
Dec 07 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Grant | A | 0.00 | 100,000 | 0 | 8,450,636 | 8.4 M to 8.5 M (+1.20 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.98 | 1,796 | 70,008 | 8,354,630 | 8.4 M to 8.4 M (-0.02 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.97 | 300 | 11,691 | 8,356,426 | 8.4 M to 8.4 M (0.00 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.96 | 1,100 | 42,856 | 8,356,726 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.95 | 900 | 35,055 | 8,357,826 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.94 | 300 | 11,682 | 8,358,726 | 8.4 M to 8.4 M (0.00 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.93 | 700 | 27,251 | 8,359,026 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.92 | 400 | 15,568 | 8,359,726 | 8.4 M to 8.4 M (0.00 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.91 | 409 | 15,914 | 8,360,126 | 8.4 M to 8.4 M (0.00 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.90 | 1,391 | 54,110 | 8,360,535 | 8.4 M to 8.4 M (-0.02 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.89 | 3,457 | 134,443 | 8,361,926 | 8.4 M to 8.4 M (-0.04 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.88 | 943 | 36,664 | 8,365,383 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.87 | 993 | 38,598 | 8,366,326 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.86 | 1,111 | 43,173 | 8,367,319 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.85 | 2,800 | 108,780 | 8,368,430 | 8.4 M to 8.4 M (-0.03 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.84 | 3,901 | 151,515 | 8,371,230 | 8.4 M to 8.4 M (-0.05 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.83 | 6,773 | 262,996 | 8,375,131 | 8.4 M to 8.4 M (-0.08 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.82 | 2,422 | 94,022 | 8,381,904 | 8.4 M to 8.4 M (-0.03 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.81 | 900 | 34,929 | 8,384,326 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.80 | 700 | 27,160 | 8,385,226 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.79 | 400 | 15,516 | 8,385,926 | 8.4 M to 8.4 M (0.00 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.78 | 200 | 7,756 | 8,386,326 | 8.4 M to 8.4 M (0.00 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.77 | 500 | 19,385 | 8,386,526 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.76 | 2,300 | 89,148 | 8,387,026 | 8.4 M to 8.4 M (-0.03 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.75 | 1,104 | 42,780 | 8,389,326 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.74 | 1,496 | 57,955 | 8,390,430 | 8.4 M to 8.4 M (-0.02 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.73 | 1,000 | 38,730 | 8,391,926 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.72 | 700 | 27,104 | 8,392,926 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.71 | 1,400 | 54,194 | 8,393,626 | 8.4 M to 8.4 M (-0.02 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.70 | 1,000 | 38,700 | 8,395,026 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.69 | 100 | 3,869 | 8,396,026 | 8.4 M to 8.4 M (0.00 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 39.10 | 100 | 3,910 | 8,350,626 | 8.4 M to 8.4 M (0.00 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 39.06 | 100 | 3,906 | 8,350,726 | 8.4 M to 8.4 M (0.00 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 39.05 | 500 | 19,525 | 8,350,826 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 39.04 | 600 | 23,424 | 8,351,326 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 39.03 | 740 | 28,882 | 8,351,926 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 39.02 | 560 | 21,851 | 8,352,666 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 39.01 | 504 | 19,661 | 8,353,226 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 39.00 | 496 | 19,344 | 8,353,730 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.99 | 404 | 15,752 | 8,354,226 | 8.4 M to 8.4 M (0.00 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.68 | 500 | 19,340 | 8,396,126 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.67 | 1,100 | 42,537 | 8,396,626 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.66 | 1,100 | 42,526 | 8,397,726 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.65 | 2,700 | 104,355 | 8,398,826 | 8.4 M to 8.4 M (-0.03 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.64 | 300 | 11,592 | 8,401,526 | 8.4 M to 8.4 M (0.00 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.62 | 100 | 3,862 | 8,401,826 | 8.4 M to 8.4 M (0.00 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.61 | 300 | 11,583 | 8,401,926 | 8.4 M to 8.4 M (0.00 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.60 | 700 | 27,020 | 8,402,226 | 8.4 M to 8.4 M (-0.01 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.58 | 100 | 3,858 | 8,402,926 | 8.4 M to 8.4 M (0.00 %) |
Jul 17 2007 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 38.57 | 800 | 30,856 | 8,403,026 | 8.4 M to 8.4 M (-0.01 %) |